Table 1 The stereotypic VH clonotypes against SARS-CoV-2 RBD in the healthy population and in SARS-CoV-2-infected patients.

Healthy population
sampleV geneJ geneCDR3 AADivergenceIsotypeOccurrence
326650IGHV3-53 / 3-66IGHJ6DLYYYGMDV0.007 ± 0.003M (100%)12
326713IGHV3-53 / 3-66IGHJ6DLYYYGMDV0.005 ± 0.010M (92.3%), G (7.7%)13
326780IGHV3-53 / 3-66IGHJ6DLYYYGMDV0.014 ± 0.010M (97.4%), G (2.6%)38
326797IGHV3-53IGHJ6DLYYYGMDV0.004M (100%)1
327059IGHV3-53 / 3-66IGHJ6DLYYYGMDV0.003 ± 0.005M (100%)8
D103IGHV3-53IGHJ6DLYYYGMDV0.008 ± 0.020M (100%)9
326650IGHV3-53 / 3-66IGHJ6DLDYYGMDV0.006 ± 0.002M (75%), G (25%)4
326713IGHV3-53 / 3-66IGHJ6DLDYYGMDV0.012 ± 0.018M (100%)4
326797IGHV3-66IGHJ6DLDYYGMDV0.055M (100%)1
327059IGHV3-53 / 3-66IGHJ6DLDYYGMDV0.001 ± 0.002M (100%)4
D103IGHV3-53IGHJ6DLDYYGMDV0.053M (100%)1
326713IGHV3-53 / 3-66IGHJ6DLVAYGMDV0.008 ± 0.011M (100%)2
326713IGHV3-53IGHJ6DLVYYGDMV0.001 ± 0.002M (100%)3
326797IGHV3-53IGHJ6DLVYYGMDV0.089 ± 0.008M (100%)2
326713IGHV3-53IGHJ6DLVVYGMDV0.024 ± 0.052M (100%)5
326780IGHV3-53 / 3-66IGHJ6DLSYYGMDV0.024 ± 0.024M (98.44%), D (0.78%), G (0.78%)128
D103IGHV3-53IGHJ6DLSYYGMDV0.022 ± 0.003M (100%)2
327059IGHV3-53IGHJ6DLGDYGMDV0.000M (100%)1
326713IGHV3-66IGHJ6DAVSYGMDV0.000 ± 0.000M (100%)2
SARS-CoV-2-infected patients
sampleV geneJ geneCDR3 AADivergenceIsotypeOccurrence
AIGHV3-53IGHJ6DLYYYGMDV0.002 ± 0.004M (5.1%), G1 (94.9%)59
BIGHV3-53IGHJ6DLYYYGMDV0.000 ± 0.000M (33.3%), G1 (66.7%)3
GIGHV3-53 / 3-66IGHJ6DLYYYGMDV0.005 ± 0.003G1 (84.6%), A1 (15.4%)14
IIGHV3-53IGHJ6DLYYYGMDV0.000 ± 0.000M (100%)4
KIGHV3-53IGHJ6DLYYYGMDV0.009 ± 0.000G1 (100%)2
AIGHV3-53IGHJ6DLAVYGMDV0.004 ± 0.000G1 (100%)2
EIGHV3-66IGHJ6DLAVYGMDV0.018 ± 0.000G1 (100%)6
AIGHV3-53IGHJ6DLDYYGMDV0.000 ± 0.000G1 (100%)3
EIGHV3-53IGHJ6DLDYYGMDV0.004 ± 0.000A1 (100%)4
IIGHV3-66IGHJ6DLDYYGMDV0.002 ± 0.003G1 (100%)5
KIGHV3-53IGHJ6DLDYYGMDV0.007 ± 0.005G1 (100%)107
MIGHV3-53IGHJ6DLDYYGMDV0.018G1 (100%)1
AIGHV3-53IGHJ6DLVAYGMDV0.008 ± 0.017G1 (100%)14
BIGHV3-53IGHJ6DLVAYGMDV0.009G1 (100%)1
EIGHV3-53IGHJ6DLVAYGMDV0.005 ± 0.002G1 (100%)6
DIGHV3-53IGHJ6DLVYYGMDV0.004G1 (100%)1
EIGHV3-53IGHJ6DLVYYGMDV0.013A1 (100%)1
FIGHV3-53IGHJ6DLVYYGDMV0.001 ± 0.003M (75%), G1 (25%)16
BIGHV3-53IGHJ6DLVVYGMDV0.002 ± 0.002M (27.3%), G1 (72.7%)11
EIGHV3-53IGHJ6DLVVYGMDV0.013 ± 0.000A2 (100%)4
HIGHV3-53IGHJ6DLVVYGMDV0.009 ± 0.000G1 (100%)7
AIGHV3-53IGHJ6DLSYYGMDV0.013 ± 0.016G1 (100%)5
FIGHV3-53IGHJ6DLSYYGMDV0.018G1 (100%)1
OIGHV3-53IGHJ6DLSYYGMDV0.000G1 (100%)1
AIGHV3-53IGHJ6DLGDYGMDV0.009 ± 0.000G1 (100%)3
EIGHV3-53IGHJ6DLGDYGMDV0.018 ± 0.019G1 (85.7%), A1 (14.3%)7
FIGHV3-53IGHJ6DLGDYGMDV0.003 ± 0.002M (92.0%), G1 (8.0%)163
HIGHV3-53IGHJ6DLGDYGDMV0.004 ± 0.000G1 (100%)8
GIGHV3-53IGHJ6DAVSYGMDV0.004 ± 0.004M (7.0%), G1 (93.0%)57
IIGHV3-53IGHJ6DAVSYGMDV0.007 ± 0.003G1 (100%)9
PIGHV3-53IGHJ6DAVSYGMDV0.000 ± 0.000G1 (100%)3
EIGHV3-53IGHJ6DLGPYGMDV0.009G1 (100%)1
IIGHV3-53 / 3-66IGHJ6DLGPYGMDV0.010 ± 0.003G3 (40%), G1 (40%), A1 (20%)4
AIGHV3-53IGHJ6DLVIYGMDV0.003 ± 0.004M (5.9%), G1 (94.1%)17
IIGHV3-66IGHJ6DLVIYGMDV0.007 ± 0.004G1 (100%)8
EIGHV3-53 / 3-66IGHJ6DLVVLGMDV0.009 ± 0.000A2 (100%)20
IIGHV3-53IGHJ6DLVVLGMDV0.000G1 (100%)1

The healthy population samples based on publicly available IGH repertoires or patient identification can be found in the sample column. Clonotypes were mapped according to identical VJ gene usage of IGHV3-53/IGHV3-66 and IGHJ6 and perfectly matched HCDR3 amino acid sequences. Read counts of the mapped sequences in the repertoires of each sample were annotated in the occurrence column. For clonotypes with multiple occurrences, the mean and standard deviation of divergence were represented. The proportion of each isotype is indicated for each sample as a percentage.